Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Proteins patents



      

This page is updated frequently with new Proteins-related patent applications.




Date/App# patent app List of recent Proteins-related patents
06/16/16
20160171173 
 Method of indentifying new uses of known drugs patent thumbnailMethod of indentifying new uses of known drugs
A method for identifying new uses of known drugs is disclosed. The method queries a database of known drugs for a query drug and finds a second drug with a similar structure.
The Research Foundation Of The City University Of New York


06/16/16
20160169907 
 Method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk patent thumbnailMethod for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk
The present invention relates to a method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk providing a solution to the problems stated in the state of the art since it provides a method which allows making a prognosis of the number of reactions that will be produced during oral immunotherapy (oit) against proteins in cow's milk and/or an estimate of the treatment time required to achieve tolerance or desensitization during oit against proteins in cow's milk and/or the need for pre-medication during oit in a human subject.. .
Fundación Para La Investigación Biomédica Del Hospital Clinico San Carlos


06/16/16
20160169900 
 Compositions, methods and kits for diagnosis of lung cancer patent thumbnailCompositions, methods and kits for diagnosis of lung cancer
Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions.
Integrated Diagnostics, Inc.


06/16/16
20160169888 
 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines patent thumbnailProteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
Rutgers, The State University Of New Jersey


06/16/16
20160169867 
 Evaporation on superhydrophobic surfaces for detection of analytes in bodily fluids patent thumbnailEvaporation on superhydrophobic surfaces for detection of analytes in bodily fluids
This disclosure provides a diagnostic system including a detection zone adapted to receive a volume of biological fluid. The detection zone includes a plurality of micro-scale and nano-scale features that render the detection zone superhydrophobic.
The Regents Of The University Of California


06/16/16
20160169864 
 Fiber coated nanopores patent thumbnailFiber coated nanopores
Provided herein are compositions, compounds, processes, and methods of use of 3d porous coating(s) on or near a nanopore(s) for analysis or detection of charged polymers such as nucleic acids, proteins, protein-nucleic acid complexes, small molecule-biological complexes, polymer-biological complexes, and/or polyelectrolytes.. .
Trustees Of Boston University


06/16/16
20160168639 
 Genetic polymorphisms associated with stroke, methods of detection and uses thereof patent thumbnailGenetic polymorphisms associated with stroke, methods of detection and uses thereof
The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to genetic polymorphisms that have utility for such uses as predicting disease risk or predicting an individual's response to a treatment such as statins, including groups of polymorphisms that may be used as a signature marker set for such uses, as well as nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection..
Celera Corporation


06/16/16
20160168620 
 Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof patent thumbnailEngineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
Methods and composition related to the engineering of a novel protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (cgl) comprising one or more amino acid substitutions and capable of degrading methionine.
Aemase, Inc.


06/16/16
20160168593 
 Methods and compositions for enhancing targeted transgene integration patent thumbnailMethods and compositions for enhancing targeted transgene integration
Disclosed herein are methods and compositions for enhancing insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease or a hemophilia by administering one or more topoisomerases inhibitors, one or more stabilizers of r loop formation or inhibitors of r-loop repair and/or one or more up-regulators of the tc-ner pathway to the target cell.. .
Sangamo Biosciences, Inc.


06/16/16
20160168582 
 Enhanced protein expression in bacillus patent thumbnailEnhanced protein expression in bacillus
The present invention provides cells that have been genetically manipulated to have an altered capacity to produce expressed proteins. In particular, the present invention relates to gram-positive microorganisms, such as bacillus species having enhanced expression of a protein of interest, wherein one or more chromosomal genes have been inactivated, and preferably wherein one or more chromosomal genes have been deleted from the bacillus chromosome.
Danisco Us Inc.


06/16/16
20160168581 

Enzymes and uses thereof


The present invention relates to novel enzymes and the uses thereof. The invention also relates to methods of producing such enzymes, coding nucleic acid molecules, recombinant cells and methods of transforming biomass from such materials.
Deinove


06/16/16
20160168559 

Biocatalytical composition


The present invention relates to means and methods for protecting proteins and protein-type compounds in industrial and other applications. In particular, the invention provides a composition comprising at least one protein or protein-type compound immobilized at the surface of a solid carrier embedded in a protective material.
Inofea Gmbh


06/16/16
20160168556 

Unglycosylated lysostaphin variant protein


Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin.
Trustees Of Dartmouth College


06/16/16
20160168383 

Cyanine compounds


Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis.

06/16/16
20160168347 

Composite carrier for immobilization of proteins, polypeptides or oligopeptides, preparation methods and application thereof


Provided are a composite carrier for immobilization of a protein, polypeptide or oligopeptide, a preparation method and an application thereof. The composite carrier is a porous material which comprises: (1) a porous organic foam material containing open pores; and (2) a crosslinked product having aldehyde groups and immobilized on the surface of the walls of one or more pores of the porous organic foam material, wherein the aldehyde groups are able to react with the protein, polypeptide or oligopeptide, and the crosslinked product are formed by chitosan via a crosslinking reaction with a polyaldehyde compound..
Bioright Worldwide Company Limited


06/16/16
20160168269 

Bi-specific fusion proteins


Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration..
Merrimack Pharmaceuticals, Inc.


06/16/16
20160168264 

Antibodies directed to her-3 and uses thereof


The present invention relates to binding proteins that bind to her-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided.
Amgen, Inc.


06/16/16
20160168261 

Immuno-pet imaging of antibodies and immunoconjugates and uses therefor


Anti-steap-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-steap-1 antibodies and immunoconjugates thereof are provided.
Genentech, Inc.


06/16/16
20160168260 

Targeted/immunomodulatory fusion proteins and methods for making same


The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.. .
Biocon Limited


06/16/16
20160168248 

Regulatory t cell mediator proteins and uses thereof


In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. Multiple sclerosis is disclosed.

06/16/16
20160168228 

Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides


Described herein is the use of elastin-like polypeptides to generate hemoglobin-based oxygen carriers as a means of preventing and treating conditions caused by blood loss or anemia, for example, hemorrhagic shock. Elastin-like polypeptides are capable of creating therapeutically functional fusion proteins through genetic engineering with a therapeutic agent, for example, hemoglobin and biologic equivalent thereof.
S-aima Holding Company, Llc


06/16/16
20160168222 

Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases


The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fgf19 and/or fgf21, and variants or fusions of fgf19 and/or fgf21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.. .
Ngm Biopharmaceuticals, Inc.


06/16/16
20160168221 

Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases


The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fgf19 and/or fgf21, and variants or fusions of fgf19 and/or fgf21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.. .
Ngm Biopharmaceuticals, Inc.


06/16/16
20160168220 

Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases


The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fgf19 and/or fgf21, and variants or fusions of fgf19 and/or fgf21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.. .
Ngm Biopharmaceuticals, Inc.


06/16/16
20160168219 

Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases


The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fgf19 and/or fgf21, and variants or fusions of fgf19 and/or fgf21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.. .
Ngm Biopharmaceuticals, Inc.


06/16/16
20160168218 

Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases


The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fgf19 and/or fgf21, and variants or fusions of fgf19 and/or fgf21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.. .
Ngm Biopharmaceuticals, Inc.


06/16/16
20160168217 

Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases


The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fgf19 and/or fgf21, and variants or fusions of fgf19 and/or fgf21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.. .
Ngm Biopharmaceuticals, Inc.


06/16/16
20160168216 

Methods of using compositions comprising variants and fusions of fgf19 polypeptides for reducing glucose levels in a subject


The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21), and variants or fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.. .
Ngm Biopharmaceuticals, Inc.


06/16/16
20160168215 

Compositions comprising variants and fusions of fgf19 polypeptides


The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21), and variants or fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.. .
Ngm Biopharmaceuticals, Inc.


06/16/16
20160168214 

Biological devices and methods of use thereof for the study and control of alzheimer's disease


Described herein are devices and methods for simultaneously expressing amyloid precursor protein and tonb protein. For example, the biological devices and methods described herein increase the production of these two proteins while also reducing the cost, making these proteins more widely accessible for medical research purposes, including for the development of diagnostic tests for alzheimer's disease.
International Park Of Creativity


06/16/16
20160168211 

Multimerization technologies


The present invention provides, among other things, dimeric multispecific binding agents (e.g., fusion proteins comprising antibody components) that have improved properties over multispecific binding agents without the capability of dimerization.. .
Memorial Sloan-kettering Cancer Center


06/16/16
20160168208 

Peptides derived from campylobacter jejuni and their use in vaccination


Disclosed are polypeptides for campylobacter jejuni that are useful as immunogenic agents for vaccine use. Also disclosed are nucleic acid fragments encoding the polypeptides as well as compositions, methods and molecular biology tools derived from or related to the proteins..
Evaxion Biotech Aps


06/16/16
20160168206 

Fine epitope peptide capable of inducing cross-reactive antibodies among homologous proteins in human papilloma virus e6 protein


This invention relates to the minimal motif of an epitope on the e6 protein from human papilloma virus (hpv), and this minimal motif of the epitope induces a monoclonal antibody having cross-reactivity with some homologous proteins of hpvs. The inventors are the first to identify a fine antigenic epitope only existing conservatively on the e6 proteins of high risk hpv16, 33, 52 or 58).
Guangzhou Hengsun Pharmaceutical Technology Co. Ltd.


06/16/16
20160168205 

Methods and compositions for labeling polypeptides


Synthesis of many proteins is tightly controlled at the level of translation and plays an essential role in fundamental processes such as cell growth and proliferation, signaling, differentiation or death. Methods that allow imaging and identification of nascent proteins allow for dissecting regulation of translation, both spatially and temporally, including in whole organisms.
President And Fellows Of Harvard College


06/16/16
20160168194 

Chromatography matrices including novel staphylococcus aureus protein a based ligands


The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, staphylococcus aureus protein a (spa), as well as methods of using the same.. .
Emd Millipore Corporation


06/16/16
20160168154 

Inhibitors of transcription factors and uses thereof


The present invention provides novel compounds of any one of formulae (i) to (iv), and pharmaceutically compositions thereof. Compounds of any one of formulae (i) to (iv) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (bets)).
University Of Massachusetts


06/16/16
20160168148 

Tricyclic heterocycles as bet protein inhibitors


The present invention relates to tricyclic heterocycles which are inhibitors of bet proteins such as brd2, brd3, brd4, and brd-t and are useful in the treatment of diseases such as cancer.. .
Incyte Corporation


06/16/16
20160167051 

Microfluidic devices and methods for cell processing


Microfluidic devices and methods that use cells such as cancer cells, stem cells, blood cells for preprocessing, sorting for various biodiagnostics or therapeutical applications are described. Microfluidics electrical sensing such as measurement of field potential or current and phenomena such as immiscible fluidics, inertial fluidics are used as the basis for cell and molecular processing (e.g., characterizing, sorting, isolation, processing, amplification.) of different particles, chemical compositions or biospecies (e.g., different cells, cells containing different substances, different particles, different biochemical compositions, proteins, enzymes etc.).
Biopico Systems Inc


06/16/16
20160166852 

X-optogenetics / u-optogenetics


Methods and systems for performing optogenetics using x-rays or ultrasound waves are provided. Visible-light-emitting nanophosphors can be provided to a sample, and x-ray stimulation can be used to stimulate the nanophosphors to emit visible light.
Rensselaer Polytechnic Institute


06/16/16
20160166718 

Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease


Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal. The methods include administering one or more of the agents of the invention to a mammal, e.g., a human.
Unity Biotechnology, Inc.


06/16/16
20160166710 

Method for increasing expression of rna-encoded proteins


The invention relates to an rna comprising at least one open reading frame (orf) and comprising at least one modification, which increases the expression of the encoded peptide or protein. Furthermore, the invention relates to the medical use of such a modified rna administered to a subject by jet injection.
Curevac Ag


06/16/16
20160166686 

Mini-intronic plasmid dna vaccines in combination with lag3 blockade


It is disclosed herein that (a) an anti-tumor dna vaccine delivered using a mip dna vector is a less effective tumor treatment than the corresponding anti-tumor dna vaccine delivered using a conventional pdna vector, despite the mip dna vector eliciting a higher frequency of antigen-specific cd8+ t cells; and (b) tumor infiltrating cd8+ t cells in animals immunized with the mip dna vector express higher levels of the immune checkpoint protein lag-3 than animals immunized with a conventional pdna vector, while the expression levels of other immune checkpoint proteins was the same for both groups. Based on these findings, improved methods and compositions for administering dna vaccines are disclosed.
Wisconsin Alumni Research Foundation


06/16/16
20160166678 

Combination vaccine


The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one rna encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a fusion (f) protein or a fragment, variant or derivative of a fusion (f) protein derived from the virus family paramyxoviridae and the second antigenic function being an hemagglutinin (ha) protein or a fragment, variant or derivative of an hemagglutinin (ha) protein derived from the virus family orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like rsv and influenza..
Curevac Ag


06/16/16
20160166677 

Computationally optimized broadly reactive antigens for h1n1 influenza


Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2012.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


06/16/16
20160166673 

Staphylococcus aureus proteins and nucleic acids


The invention provides proteins from staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics..
Glaxosmithkline Biologicals Sa


06/16/16
20160166672 

Atoxic recombinant holotoxins of clostridium difficile as immunogens


Compositions, methods and kits are provided for preparing an atoxic c. Difficile protein that elicits an immune response in the subject specific for tcda and tcdb.
Tufts University


06/16/16
20160166671 

Clostridium difficile compositions and methods of use


Fusion proteins include full-length flagellin or portions of flagellin fused to at least one clostridium difficile antigen. Fusion proteins can include a first clostridium difficile antigen that replaces at least a portion or the entirety of domain 3 of flagellin and a second clostridium difficile antigen fused to the carboxy terminal amino acid of flagellin.
Vaxinnate Corporation


06/16/16
20160166667 

Divalent vaccine compositions and the use thereof for treating tumors


The invention describes vaccine compositions combined in the same proportion with the extracellular domains of growth factor receptors her1 and her2 or fragments thereof and furthermore very small size proteoliposomes derived from proteins of the outer membrane of neisseria meningitidis and gm3 ganglioside (vssp-gm3), administered subcutaneously. The disclosed compositions, which induce the production of antibodies are used for the treatment of malignancies and offer advantages because they completely remove the tumor mass thus preventing tumor regression due to the emergence of resistant variants..
Centro De Inmunologia Molecular


06/16/16
20160166664 

Compositions and methods for induction of antigen-specific tolerance


The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect.
Northwestern University


06/16/16
20160166663 

Vaccine formulations that induce a th2 immune response


The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the present invention comprise a vaccine formulation comprising an antigen selected from the group consisting of i) amyloid-β or a peptide that has in its amino acid sequence part of the amyloid-β amino acid sequence, ii) hyperphosphorylated tau protein or one of its hyperphoshorylated peptides, or iii) a combination of antigens derived from groups i) and ii) and that are formulated with a non-acylated or deacylated, natural or synthetic, bidesmosidic triterpene glycoside carrying an aldehyde or ketone group, which acts as an adjuvant or immune agonist.
Qantu Therapeutics, Inc.


06/16/16
20160166645 

Treatment of collagen defects using protein solutions


Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group il-1ra, stnf-ri, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii..
Biomet Biologics, Llc


06/16/16
20160166642 

Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases


The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fgf19 and/or fgf21, and variants or fusions of fgf19 and/or fgf21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.. .
Ngm Biopharmaceuticals, Inc.


06/16/16
20160166600 

Therapy-enhancing glucan


This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions.
Sloan-kettering Institute For Cancer Research


06/16/16
20160166596 

Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer


Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase.. .
Nucana Biomed Limited


06/16/16
20160166549 

Bcl6 inhibitors as anticancer agents


The invention provides compositions and methods for blocking the bcl6 btb domain with small molecule, non-peptide compounds as disclosed and claimed herein. Bcl6 is a transcriptional repressor of the btb-poz (brie a brae, tramtrack, broad complex/pox virus zincfinger) family of proteins.
University Of Maryland, Baltimore


06/16/16
20160165860 

Domain 5 of cd163 for use in antiviral compositions against prrs, and transgenic animals


The present invention relates to methods and compositions useful for the prevention and/or treatment of prrs in animals, typically domestic pigs. The invention relates to proteins which comprise fragments of cd163, nucleic acid constructs encoding such proteins, and methods of modifying expression or activity of cd163 in vivo..
The University Court Of The University Of Edinburg H


06/09/16
20160161493 

Compositions, methods and kits for diagnosis of lung cancer


The present invention provides methods for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. The present invention also provides compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions.
Integrated Diagnostics, Inc.


06/09/16
20160161481 

Method for detecting indicators for determining diseases


The invention concerns a method for detecting indicators for determining diseases (disease indicators), in which aggregates of misfolded proteins play a role, and a method for selective quantitation and/or characterization of these disease indicators.. .
Forschungszentrum Jülich Gmbh


06/09/16
20160161470 

Modulation of axon degeneration


The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons..
Genentech, Inc.


06/09/16
20160160268 

Amdinocillin for rapid determination of susceptibility to beta-lactam antibiotics


Described are methods for detecting susceptibility of a specimen to antibiotics, and particularly for enhancing such susceptibility testing for beta lactam antibiotics and antibiotics that bind to penicillin-binding proteins. The method comprises contacting the specimen with an oligonucleotide probe that specifically hybridizes with a target nucleic acid sequence region of ribosomal rna.
United States Government Represented By The Department Of Veterans Affairs


06/09/16
20160160254 

Plants expressing cell wall degrading enzymes and expression vectors


Vectors for expression of proteins in plants are described. The proteins may be enzymes and the enzymes can be but are not limited to cell wall degrading enzymes.
Agrivida, Inc.


06/09/16
20160160229 

Methods of producing antibody-rich cannabis and honeysuckle plants


A method of producing antibody-rich cannabis and honeysuckle plants, and receiving the antibodies therefrom within a human body, is described. Antibody proteins are transfected or transduced to the dna of one or more cells of a cannabis or honeysuckle seed.
Thc Farmaceuticals, Inc.


06/09/16
20160160228 

Transgenic aloe plants for production of proteins and related methods


The present inventions provide transgenic aloe plants and recombinant constructs for transforming aloe plants, aspects of which, may be applied to other monocots. The recombinant constructs may include one or more dna sequences encoding mammalian proteins and at least one promoter capable of directing the expression of recombinant proteins in an aloe plant.
Thegreencell, Inc.


06/09/16
20160160169 

Analysis and screening of poly-functional secretion profiles


Embodiments disclose apparatus, methods and software for performing biological screening and analysis implemented using an instrument platform capable of detecting a wide variety of cell-based secretions, expressed proteins, and other cellular components. The platform may be configured for simultaneous multiplexed detection of a plurality biological components such that a large number of discrete samples may be individually sequestered and evaluated to detect or identify constituents from the samples in a highly parallelized and scalable manner..
Isoplexis Corporation


06/09/16
20160160048 

Polymers and plastics derived from animal proteins


The invention is directed to a method for preparing a polymer derived from an animal protein, such as in a feedstock derived from animal by-products. The method involves hydrolyzing proteins present in a feedstock to obtain hydrolyzed proteins, wherein hydrolysis is conducted under conditions sufficient to digest the proteins and destroy pathogens; extracting a protein fraction from the hydrolyzed proteins; and treating the protein fraction with a crosslinking reagent to form the polymer.
The Governors Of The University Of Alberta


06/09/16
20160159927 

Identification of vsig8 as the putative vista receptor (v-r) and use thereof to produce vista/vsig8 agonists and antagonists


The receptor for vista is identified (vsig8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of vsig8 and/or vista and/or the vsig8/vista binding interaction. These antagonists may be used to suppress vista's suppressive effects on t cell immunity, and more particularly used in the treatment of cancer, or infectious disease.
Immunext, Inc.


06/09/16
20160159923 

Antibodies to matrix metalloproteinase 9


The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.


06/09/16
20160159920 

Coiled coil immunoglobulin fusion proteins and compositions thereof


Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide.
The California Institute For Biomedical Research


06/09/16
20160159898 

Methods of producing two chain proteins in bacteria


Provided herein are methods of producing a polypeptide containing two chains, such as an antibody including a light chain and a heavy chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes..
Genentech, Inc.


06/09/16
20160159897 

Low mannose adalimumab compositions and uses thereof


The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells by supplementing the production media with dissolved oxygen.. .
Abbvie Inc.


06/09/16
20160159883 

Fibronectin based scaffold domain proteins that bind pcsk9


The present invention relates to fibronectin based scaffold domain proteins that bind pcsk9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases.
Bristol-myers Squibb Company


06/09/16
20160159880 

Methods of producing two chain proteins in bacteria


Provided herein are methods of producing a recombinant polypeptide containing two chains, such as an immune mobilizing monoclonal t-cell receptor against cancer (immtac) protein including an alpha chain and a beta chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes..
Genentech, Inc.


06/09/16
20160159879 

Regulation of sodium channels by plunc proteins


The present invention relates to the ability of plunc proteins, such as splunc1 and splunc2, to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of plunc proteins to sodium channels..
The University Of North Carolina At Chapel Hill


06/09/16
20160159878 

Nogo receptor antagonists


Disclosed are immunogenic nogo receptor-1 polypeptides, nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are nogo receptor antagonist polynucleotides.
Biogen Ma Inc.


06/09/16
20160159873 

Research bio-nanoparticle elements and platforms


The invention in suitable embodiments is directed to research bio-nanoparticle elements and research bio-nanoparticle platforms employing such research bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of clathrin protein and/or non-clathrin coatomer proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro..

06/09/16
20160159868 

Production of soy protein products with reduced astringency (ii)


The present invention is directed to soy protein products of reduced astringency. The reduced astringency soy protein products of the present invention may be obtained by using membrane processing to fractionate soy protein solutions, which provide soy protein products which are completely soluble and heat stable in aqueous media at acid ph value of less than about 4.4, into lower molecular weight, less astringent proteins and higher molecular weight, more astringent proteins..
Burcon Nutrascience (mb) Corp.


06/09/16
20160159867 

Nucleotide sequences, vectors and host cells


Polynucleotides encoding fusion proteins comprising fragments of toxin a and toxin b from clostridium difficile are described, as well as vectors and host cells containing such polynucleotides.. .
Glaxosmithkline Biologicals S.a.


06/09/16
20160159866 

Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use


The present invention is directed to a fusion protein comprising a light chain region of a clostridial neurotoxin and a heavy chain region of a clostridial neurotoxin, where the light and heavy chain regions are linked by a disulfide bond. The fusion protein also has a single chain antibody positioned upstream of the light chain region, where the single chain antibody possesses antigen-binding activity.
New York University


06/09/16
20160159865 

Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof


Non-naturally occurring factor h binding proteins derived from variant 3 fhbp that can elicit antibodies that are bactericidal for at least one strain of n. Meningitidis, and methods of use of such proteins, are provided.
Children's Hospital & Research Center Oakland


06/09/16
20160159864 

Complexes of cytomegalovirus proteins


This disclosure provides an isolated human cytomegalovirus (hcmv) membrane protein complex, wherein said complex comprises gh, gl and at least one more hcmv glycoprotein. In some embodiments the complex consists of gh, gl and go.
Novartis Ag


06/09/16
20160159856 

Affinity tags and processes for purifying and immobilizing proteins using same


The present disclosure provides affinity tags, fusion proteins comprising one or more affinity tags, compositions comprising a fusion protein, methods of purifying a protein using an affinity tag, and devices for purifying a protein using an affinity tag.. .
University Of Washington Through Its Center For Commercialization


06/09/16
20160159854 

Concentration and purification of hydrophobins and antibodies with a phase separation method


The present invention relates to a purification and concentration method for proteins and antibodies. Particularly the present invention relates to a continuous surfactant based phase separation method for recovering hydrophobin fusion proteins, and for recovering target molecules, such as antibodies, directly from a liquid by using phase separation and hydrophobin-protein a fusion technologies..
Teknologian Tutkimuskeskus Vtt Oy


06/09/16
20160159853 

Apparatus for refolding of recombinant proteins


A machine or apparatus for refolding a protein of interest produced recombinantly in a host cell in form of inclusion bodies is provided. The apparatus includes an inclusion bodies (ib) solubilisation tank to solubilise the inclusion bodies; a plurality of refolding vessels or reactors arranged in series to receive a refolding feed; a first tank connected to the ib solubilisation tank to hold diafiltration buffer or agent; a first diafiltration cartridge having at least one permeate end and one retentate end, connected to the ib solubilisation tank, through a first retentate end to feed the refolding feed to the ib solubilisation tank; a second tank, connected to the first permeate end of the diafiltration cartridge to receive and recycle the refolding buffer and each of the refolding vessels, for supplying refolding buffer or agent to each of the refolding vessels..
Biogenomics Limited


06/09/16
20160159817 

Tricyclic heterocycles as bet protein inhibitors


The present invention relates to tricyclic heterocycles of formula (i), which are inhibitors of bet proteins such as brd2, brd3, brd4, and brd-t and are useful in the treatment of diseases such as cancer.. .
Incyte Holdings Corporation






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.8155

4651

1 - 1 - 103